Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Job Board

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

New study reveals vormatrigine significantly reduces focal onset seizures, offering hope for improved epilepsy treatments at the upcoming International Epilepsy Congress.

Praxis’ Vormatrigine Shows Significant Ability to Reduce Seizure Incidence in Phase 2 RADIANT Study

Videos

The associate professor of neurology at Johns Hopkins Medicine previewed a 2025 AUPN panel exploring AI’s clinical, research, and educational applications, along with the ethical considerations shaping its responsible adoption. [WATCH TIME: 2 minutes]

Preparing for the AI-Driven Future of Neurology: Elisabeth Marsh, MD

Richard Kovacs, MD, PhD, chief medical officer for the American College of Cardiology, discusses interim XYLO trial results, highlighting how switching to low-sodium oxybate can significantly impact blood pressure and cardiovascular risk profiles in narcolepsy.

Reducing Sodium in Narcolepsy Treatment: Cardiovascular Insights From the XYLO Trial

The chief medical officer at Acumen Pharmaceuticals discussed the benefits of using the blood-based p-tau 217 biomarker to improve screening accuracy and reduce patient burden in AD. [WATCH TIME: 5 minutes]

Advances in Alzheimer Disease Screening and Antibody Therapy at AAIC 2025: Eric Siemers, MD

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

Director of the Center for Cognitive Health at the Icahn School of Medicine at Mount Sinai.

Sam Gandy, MD, PhD, director of the Center for Cognitive Health at the Icahn School of Medicine at Mount Sinai, discussed his presentation on detecting toxic amyloid-β oligomers and their role in AD pathology at AAIC 2025. 

Targeting Amyloid-ß Oligomers With Investigational Alzheimer Disease Therapy Valiltramiprosate

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Alexa Dessy, MD. [LISTEN TIME: 17 minutes]

Episode 147: Improving Quality of Life in Movement Disorders Through Nonmotor Symptom Management

, has been with the team since September 2022. Follow her on Twitter 

The advisory board member of the Parkinson's Foundation shared personal insights on how love, present-moment awareness, and hope shaped her approach to living with the Parkinson disease. [WATCH TIME: 6 minutes]

Prescription of Love, Mindfulness, and Hope in Parkinson Disease Care: Esther Labib-Kiyarash, MSHA, CPHQ

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AAIC 2025

CMSC 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Alzheimer’s Disease Treatment Landscape Evolutions

Emerging Agents for Treatment of Alzheimer’s Disease

Evolving Pathophysiology of Alzheimer’s Disease

Management of Alzheimer’s Disease with FDA-approved Disease-modifying Therapies

Symptom Management Agents for Patients with Alzheimer’s Disease

Biomarkers in Alzheimer’s Disease

Future Outlook of Alzheimer’s Disease

Lasso - DMD Peers and Perspectives NSP-21-NRD0157

 video series brings together pairs of expert clinicians and physicians to independently provide their insights on the latest and most up-to-date clinical care for specific neurologic diseases and disorders.

Emerging Agents for Treatment of Alzheimer’s Disease

EP: 1.Evolving Pathophysiology of Alzheimer’s Disease

EP: 2.Management of Alzheimer’s Disease with FDA-approved Disease-modifying Therapies

EP: 3.Emerging Agents for Treatment of Alzheimer’s Disease

EP: 4.Symptom Management Agents for Patients with Alzheimer’s Disease

EP: 5.Biomarkers in Alzheimer’s Disease

EP: 6.Future Outlook of Alzheimer’s Disease

Newsletter